Extended Data Fig. 2: RNA-seq and Tumor Purity Validation of PDCs. | Nature Medicine

Extended Data Fig. 2: RNA-seq and Tumor Purity Validation of PDCs.

From: Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers

Extended Data Fig. 2

Immune cell type deconvolution and tumor purity analysis was done from original tissue (T) and PDCs (when available). a) Analysis of EV004-RMS. Bulk RNA-seq was deconvoluted using the analysis tools EPIC (Top Left, T and PDC) and quanTIseq (Bottom Left, T and PDC). Immune cell composition (T and PDC) was analyzed using TIMER (Top Right). Tumor purity analysis was done using pathology analysis (T, in green), ESTIMATE (T and PDC, in blue), quanTIseq (T and PDC, in purple), and EPIC (T and PDC, in yellow). A similar approach was used in b) EV009-OS, c) EV007-GBM, d) EV002-AML and e) EV013-AML.

Back to article page